The Current and Future State of Immune Checkpoint Inhibitors in NSCLC

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.

Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.